Clinical Trial Update: Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the combination of imatinib mesylate (Gleevec) and sorafenib in androgen-independent prostate cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Gleevec (imatinib mesylate) (imatinib mesylate)
• Nexavar (sorafenib) (sorafenib)

Snippet

Sponsor: Oncology Specialists, S.C. | Conditions: Prostate Cancer | Phase 1 | Status: COMPLETED | Results posted: 2014-07-21